drugset / Trial / NCT00362726

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

NCT00362726

Phase 1 Completed 14 enrolled Bristol-Myers Squibb
Non-randomizedCrossoverOpen-label

Summary

The purpose of this clinical research study is to assess the effect of Atazanavir 400 mg QD and Atazanavir/Ritonavir 300/100 mg QD at steady state on the single dose pharmacokinetics of RGZ in healthy subjects.

Timeline

Start
2006-09
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg Oral
Comparator Atazanavir Other / unclassified 400 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral
Comparator Rosiglitazone Small molecule 4 mg Oral